Full Press Release Details
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include: Third Quarter and Recent Highlights YARTEMLEA® (narsoplimab-wuug), the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”), an often-lethal complication of stem cell transplantation, generated gross revenue of $41.8 million in the third qua